Insurers Are Pulling Back From GLP-1 Drugs. The FDA Just Handed Eli Lilly Its Best Weapon Yet

Employer coverage of GLP-1 drugs is projected to keep shrinking into 2027, but the FDA’s latest action for Eli Lilly provides a new payer-facing argument that could improve reimbursement prospects for at least a portion of the market. Overall, the setup is still pressure-heavy on coverage, yet Lilly receives a near-term regulatory tailwind that may support contracting and formulary discussions.